InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,312.80
(
0.08%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
74.13
(
0.53%
)
Bitcoin
63,299.19
(
-0.05%
)
Post# of 253199
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120482
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Titan V post# 216415

Monday, 12/10/2018 8:32:43 AM

Monday, December 10, 2018 8:32:43 AM

Post# of 253199
AXON -22%/PM on phase-2 failure:

https://globenewswire.com/news-release/2018/12/10/1664256/0/en/Axovant-Reports-Results-of-Exploratory-Phase-2-Clinical-Study-of-Nelotanserin-in-Lewy-Body-Dementia-Patients-Experiencing-REM-Sleep-Behavior-Disorder.html

Axovant Sciences…today reported topline results of the 34-patient, exploratory phase 2 clinical study of nelotanserin for the treatment of REM sleep behavior disorder (RBD) in patients with Lewy body dementia (LBD). The primary efficacy endpoint of reduction in frequency of RBD events as measured by sleep laboratory video assessment was not met.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up